# Mark Egly Foundation - Master Project Plan

**Mission**: Ending diagnostic delays and improving outcomes for Alpha-1 Antitrypsin Deficiency (AATD) patients through education, research, advocacy, and support.

**Founded by**: Mark Egly, PGA Member  
**Project Start**: November 7, 2025

---

## ðŸŽ¯ Foundation Overview

### The Problem

**Alpha-1 Antitrypsin Deficiency (AATD)** is an orphan genetic disease that:
- Takes **7-8 years** and **4+ medical professionals** to diagnose on average
- Is often misdiagnosed as asthma or COPD
- Affects lung and liver function
- Is inherited genetically (Mark's children each have at least one mutated gene)
- New science shows even **MZ carriers** (one mutated gene) can have medical issues
- Is preventable/manageable with early detection and treatment

### Mark's Story

Mark Egly had to **self-diagnose** his AATD after years of symptoms. This diagnostic odyssey inspired him to:
1. Found this foundation to prevent others from the same struggle
2. Secure a **patent for repurposing AAT protein** ([Patent US20220160847](https://patents.justia.com/patent/20220160847))
3. Advocate for newborn screening and early detection
4. Build education programs for medical professionals

### Foundation Goals

**Primary Objectives**:
1. **Reduce diagnostic delay** from 7-8 years to <1 year
2. **Educate medical professionals** about AATD recognition
3. **Support patients** through testing, treatment, and community
4. **Advance research** into testing, treatment, and prevention
5. **Advocate for policy changes** (newborn screening, protected status)
6. **Commercialize innovations** (AAT glucometer, Mark's patent, etc.)

---

## ðŸ“‹ Master Project Plan

**Total Documents**: ~60 comprehensive strategy and program documents  
**Estimated Timeline**: 10 weeks (phased approach)  
**Total Scope**: Complete foundation infrastructure from mission to operations

### Phase 1: Foundation (Weeks 1-2) â­ **CURRENT PHASE**

**Documents**:
1. âœ… Mission, Vision & Values Statement
2. âœ… Theory of Change Framework
3. âœ… Strategic Plan (3-5 Year Roadmap)
4. âœ… Impact Measurement Framework
5. âœ… Annual Goals & OKRs (2026)
6. âœ… Board Governance & Bylaws
7. âœ… Financial Management & 501(c)(3) Compliance
8. âœ… Team Structure & Hiring Roadmap
9. âœ… Volunteer Program Development
10. âœ… Brand Guidelines & Visual Identity
11. âœ… Messaging Framework & Talking Points
12. âœ… Storytelling & Case Studies Template

**Why First**: Establishes the foundation's north star, governance structure, brand identity, and operational framework before building programs.

---

### Phase 2: Patient Impact (Weeks 3-4)

**Patient Education & Resources** (4 docs):
- What is AATD? Comprehensive guide
- Living with AATD handbook
- Testing & diagnosis roadmap
- Treatment options guide

**Community & Support Network** (4 docs):
- Alpha1Life.com strategy & content plan
- Support group development guide
- Patient navigation program
- Community engagement & storytelling

**Why Second**: Direct patient impact builds community and demonstrates value immediately.

---

### Phase 3: Medical Education (Weeks 5-6)

**Medical Education Program** (4 docs):
- CME-accredited courses for physicians
- Diagnostic delay education (malpractice risk)
- AATD certification seal program (like Fair Underwriting)
- Medical institution partnership playbook

**Innovation Initiatives** (5 docs):
- Quick circulating AAT testing device
- DNA testing simplification strategy
- ZZ protein identification test recovery
- Novel administration methods research
- Gene therapy research partnerships

**Why Third**: Core to reducing diagnostic delayâ€”the foundation's primary mission.

---

### Phase 4: Fundraising & Growth (Weeks 7-8)

**Grants IN Strategy** (4 docs):
- Grant identification & tracking system
- Grant application playbook
- Foundation grant sources database
- Grant calendar & pipeline

**Grants OUT Program** (4 docs):
- Patient assistance program (testing & treatment)
- Research grant program
- Grant application process & criteria
- Grant management & reporting

**Fundraising Strategy** (5 docs):
- Major donor identification & cultivation
- Corporate partnership strategy
- Employee giving programs
- Fundraising events playbook
- Donor stewardship & retention

**Partnership Strategy** (4 docs):
- Similar organizations database (Michael J. Fox model)
- Academic/research institution partnerships
- Pharmaceutical company partnerships
- Genetic testing company partnerships (23andMe, etc.)

**Why Fourth**: Need funding to scale all programs sustainably.

---

### Phase 5: Advocacy & Scale (Weeks 9-10)

**Advocacy & Policy Strategy** (5 docs):
- Legislative priorities (child testing, protected status)
- Newborn screening advocacy campaign
- Occupational health policy (firefighters, military)
- Insurance & coverage advocacy
- Policy toolkit & talking points

**Research & Innovation Strategy** (5 docs):
- Research priorities & roadmap
- Mark's patent commercialization strategy
- AAT 'glucometer' device development plan
- Mass protein production initiatives
- Repurposing research (firefighters, asthma, military)

**Website Strategy** (3 docs):
- MarkeGlyFoundation.com redesign & IA
- Content strategy & SEO plan
- Digital marketing & social media strategy

**Data & Research Database** (3 docs):
- Anonymous data donation program
- Tax deduction strategy for DNA sequence donation
- Research database architecture & governance

**Why Last**: Requires momentum, resources, and credibility to execute effectively.

---

## ðŸ”‘ Key Strategic Initiatives

### Immediate High-Impact Programs

**1. AATD Certification Seal Program** (Like Fair Underwriting)
- Medical institutions get "AATD Aware" certification
- Demonstrates commitment to early detection
- Provides education materials and protocols
- Marketing benefit for participating institutions

**2. Physician Malpractice Education**
- CME-accredited courses on diagnostic delay risks
- Legal case studies of missed AATD diagnoses
- Differential diagnosis protocols
- Risk mitigation strategies

**3. Newborn Screening Advocacy**
- Push for AATD inclusion in state newborn screening panels
- Model legislation for all 50 states
- Evidence-based policy briefs
- Coalition building with other rare disease groups

**4. AAT "Glucometer" Device**
- Portable device to measure circulating AAT levels
- Enables real-time monitoring (like diabetes management)
- Early warning system for exacerbations
- Could be breakthrough product

**5. Data Donation Tax Deduction Program**
- Novel approach: tax write-off for DNA sequence donation
- Builds comprehensive research database
- Anonymized data for research
- Incentivizes participation

### Innovative Ideas & Recommendations

**Partnerships**:
- **23andMe/Ancestry.com**: Flag AATD carriers in existing databases
- **Pharmaceutical Companies**: AAT replacement therapy manufacturers
- **Medical Schools**: Integrate AATD into curriculum
- **Firefighter Unions**: Occupational health advocacy (smoke exposure)
- **Military**: Mandatory screening for service members

**Revenue Streams** (Sustainability):
- Mark's patent licensing (repurposed AAT protein)
- AAT glucometer device commercialization
- Certification seal program fees (nominal)
- Corporate sponsorships
- Major donor cultivation

**Occupational Focus Areas**:
- **Firefighters**: High smoke exposure accelerates AATD
- **Military**: Combat exposures (burn pits, smoke)
- **Asthma Misdiagnosis**: "Not all asthma is asthma" campaign

---

## ðŸŒ Digital Properties

### Current Websites

**Mark Egly Foundation** - https://old.markeglyfoundation.com
- **Purpose**: Education for medical professionals and public
- **Status**: Needs redesign
- **Content**: AATD info, testing resources, research updates

**Alpha1Life.com** - (Patient-focused community site)
- **Purpose**: Patient support, community, end-user education
- **Status**: To be developed
- **Content**: Personal stories, support groups, living with AATD

### Patent

**Repurposing Alpha-1 Antitrypsin**  
Patent US20220160847  
https://patents.justia.com/patent/20220160847

**Applications**:
- Other diseases
- Firefighter protection
- Asthma treatment
- Armed forces health
- Novel administration methods

---

## ðŸŽ¯ Success Metrics (Impact Framework)

### Patient Impact
- **Diagnostic Delay**: Reduce average from 7-8 years to <1 year
- **Patients Helped**: Test & treat X patients annually
- **Community Size**: Y active community members

### Medical Education
- **Physicians Trained**: CME courses completed
- **Institutions Certified**: "AATD Aware" seal recipients
- **Awareness**: % of physicians who can identify AATD symptoms

### Research & Innovation
- **AAT Glucometer**: Device to market timeline
- **Patent Licensing**: Commercial partnerships
- **Research Database**: Anonymous genetic samples collected

### Advocacy
- **Policy Wins**: States with newborn AATD screening
- **Protected Status**: AATD recognized as protected condition
- **Insurance Coverage**: Improved coverage for testing/treatment

### Financial Sustainability
- **Funding Secured**: Annual grant revenue
- **Patient Assistance**: $ distributed to patients in need
- **Operating Reserve**: Months of operating expenses

---

## ðŸ“ž Stakeholder Groups

### Primary Stakeholders

**Patients**:
- Currently diagnosed AATD patients
- Undiagnosed patients (misdiagnosed as asthma/COPD)
- MZ carriers (one mutated gene)
- Family members at risk

**Medical Professionals**:
- Primary care physicians
- Pulmonologists
- Hepatologists
- Genetic counselors
- Medical residents & students

**Researchers**:
- Academic institutions
- Pharmaceutical companies
- Medical device developers
- Genetic testing companies

**Policymakers**:
- State legislators (newborn screening)
- Federal legislators (protected status)
- Insurance regulators
- Public health officials

**Occupational Groups**:
- Firefighters & fire departments
- Military personnel
- Industrial workers (smoke/chemical exposure)

### Similar Organizations (Benchmarks)

**Michael J. Fox Foundation** (Parkinson's)
- Model for patient-funded research acceleration
- $2 billion+ in research funded
- Public awareness campaigns
- Major donor cultivation strategies

**Cystic Fibrosis Foundation**
- Drug development model (royalties fund foundation)
- Newborn screening advocacy success
- Patient registry for research

**Other AATD Organizations**:
- Alpha-1 Foundation
- AlphaNet (patient support)
- COPD Foundation

---

## ðŸ“ Document Structure

```
/MARK_EGLY_FOUNDATION/
â”œâ”€â”€ README.md (this file)
â”œâ”€â”€ /strategy/
â”‚   â”œâ”€â”€ MISSION-VISION-VALUES.md
â”‚   â”œâ”€â”€ THEORY-OF-CHANGE.md
â”‚   â”œâ”€â”€ STRATEGIC-PLAN-2025-2030.md
â”‚   â”œâ”€â”€ IMPACT-MEASUREMENT-FRAMEWORK.md
â”‚   â””â”€â”€ ANNUAL-GOALS-OKRS-2026.md
â”œâ”€â”€ /operations/
â”‚   â”œâ”€â”€ BOARD-GOVERNANCE-BYLAWS.md
â”‚   â”œâ”€â”€ FINANCIAL-MANAGEMENT-501C3.md
â”‚   â”œâ”€â”€ TEAM-STRUCTURE-HIRING.md
â”‚   â””â”€â”€ VOLUNTEER-PROGRAM.md
â”œâ”€â”€ /brand/
â”‚   â”œâ”€â”€ BRAND-GUIDELINES.md
â”‚   â”œâ”€â”€ MESSAGING-FRAMEWORK.md
â”‚   â””â”€â”€ STORYTELLING-CASE-STUDIES.md
â”œâ”€â”€ /medical-education/
â”‚   â”œâ”€â”€ CME-COURSES.md
â”‚   â”œâ”€â”€ DIAGNOSTIC-DELAY-EDUCATION.md
â”‚   â”œâ”€â”€ CERTIFICATION-SEAL-PROGRAM.md
â”‚   â””â”€â”€ MEDICAL-PARTNERSHIPS.md
â”œâ”€â”€ /patient-education/
â”‚   â”œâ”€â”€ WHAT-IS-AATD.md
â”‚   â”œâ”€â”€ LIVING-WITH-AATD-HANDBOOK.md
â”‚   â”œâ”€â”€ TESTING-DIAGNOSIS-ROADMAP.md
â”‚   â””â”€â”€ TREATMENT-OPTIONS-GUIDE.md
â”œâ”€â”€ /community/
â”‚   â”œâ”€â”€ ALPHA1LIFE-STRATEGY.md
â”‚   â”œâ”€â”€ SUPPORT-GROUP-GUIDE.md
â”‚   â”œâ”€â”€ PATIENT-NAVIGATION-PROGRAM.md
â”‚   â””â”€â”€ COMMUNITY-ENGAGEMENT.md
â”œâ”€â”€ /research/
â”‚   â”œâ”€â”€ RESEARCH-PRIORITIES.md
â”‚   â”œâ”€â”€ PATENT-COMMERCIALIZATION.md
â”‚   â”œâ”€â”€ AAT-GLUCOMETER-PLAN.md
â”‚   â”œâ”€â”€ MASS-PROTEIN-PRODUCTION.md
â”‚   â””â”€â”€ REPURPOSING-RESEARCH.md
â”œâ”€â”€ /innovation/
â”‚   â”œâ”€â”€ QUICK-AAT-TESTING-DEVICE.md
â”‚   â”œâ”€â”€ DNA-TESTING-SIMPLIFICATION.md
â”‚   â”œâ”€â”€ ZZ-PROTEIN-IDENTIFICATION.md
â”‚   â”œâ”€â”€ NOVEL-ADMINISTRATION.md
â”‚   â””â”€â”€ GENE-THERAPY-PARTNERSHIPS.md
â”œâ”€â”€ /grants-in/
â”‚   â”œâ”€â”€ GRANT-IDENTIFICATION-TRACKING.md
â”‚   â”œâ”€â”€ GRANT-APPLICATION-PLAYBOOK.md
â”‚   â”œâ”€â”€ GRANT-SOURCES-DATABASE.md
â”‚   â””â”€â”€ GRANT-CALENDAR-PIPELINE.md
â”œâ”€â”€ /grants-out/
â”‚   â”œâ”€â”€ PATIENT-ASSISTANCE-PROGRAM.md
â”‚   â”œâ”€â”€ RESEARCH-GRANT-PROGRAM.md
â”‚   â”œâ”€â”€ GRANT-APPLICATION-PROCESS.md
â”‚   â””â”€â”€ GRANT-MANAGEMENT-REPORTING.md
â”œâ”€â”€ /fundraising/
â”‚   â”œâ”€â”€ MAJOR-DONOR-STRATEGY.md
â”‚   â”œâ”€â”€ CORPORATE-PARTNERSHIPS.md
â”‚   â”œâ”€â”€ EMPLOYEE-GIVING-PROGRAMS.md
â”‚   â”œâ”€â”€ FUNDRAISING-EVENTS-PLAYBOOK.md
â”‚   â””â”€â”€ DONOR-STEWARDSHIP.md
â”œâ”€â”€ /advocacy/
â”‚   â”œâ”€â”€ LEGISLATIVE-PRIORITIES.md
â”‚   â”œâ”€â”€ NEWBORN-SCREENING-CAMPAIGN.md
â”‚   â”œâ”€â”€ OCCUPATIONAL-HEALTH-POLICY.md
â”‚   â”œâ”€â”€ INSURANCE-COVERAGE-ADVOCACY.md
â”‚   â””â”€â”€ POLICY-TOOLKIT.md
â”œâ”€â”€ /partnerships/
â”‚   â”œâ”€â”€ SIMILAR-ORGANIZATIONS-DATABASE.md
â”‚   â”œâ”€â”€ ACADEMIC-PARTNERSHIPS.md
â”‚   â”œâ”€â”€ PHARMACEUTICAL-PARTNERSHIPS.md
â”‚   â””â”€â”€ GENETIC-TESTING-PARTNERSHIPS.md
â”œâ”€â”€ /data/
â”‚   â”œâ”€â”€ DATA-DONATION-PROGRAM.md
â”‚   â”œâ”€â”€ TAX-DEDUCTION-STRATEGY.md
â”‚   â””â”€â”€ RESEARCH-DATABASE-ARCHITECTURE.md
â””â”€â”€ /website/
    â”œâ”€â”€ WEBSITE-REDESIGN-IA.md
    â”œâ”€â”€ CONTENT-STRATEGY-SEO.md
    â””â”€â”€ DIGITAL-MARKETING-SOCIAL.md
```

---

## ðŸš€ Next Steps

### Phase 1 - NOW (Weeks 1-2)
**Create foundation documents** in `/strategy/`, `/operations/`, and `/brand/`

**Current Status**: Starting Phase 1, Document 1
- âœ… Master plan created
- ðŸ”„ Now creating: Mission, Vision & Values Statement

---

**Last Updated**: November 7, 2025  
**Project Lead**: Mark Egly  
**Documentation By**: AI Assistant  
**Status**: Phase 1 - Foundation Strategy (In Progress)
